Influenza Diagnostics Market – Enhanced Acceptance Of In Vitro Diagnostic Tests Will Drive Market Growth
Influenza is a seasonal disease caused by influenza virus. In the US, influenza is prevalent in the fall of winter, with major activity being reported in the month of October. The disease burden for children aged 5 years or older is high and is reported to be the key reason of death in the elderly population. In the U.S., CDC through its national influenza surveillance system, tracks the disease growth, death percentage, hospitalizations, etc.
"A large number of diagnostic tests available for the diseases"
The diagnosis of influenza is done mainly by Rapid Influenza Diagnostic Tests (RIDTs), reverse transcription polymerase chain reaction (RT-PCR), culture, serology, and immunofluorescence assays. Among these tests, RIDTs are the most popular due to their rapid detection rate and accurate results. Results from these tests are available in very short duration. RIDTs are of significant medical value and their usage becomes high during the flu season. RT-PCRs are also advantageous in rapidly detecting influenza viruses as well as the emergence of new viruses. According to the WHO, numerous PCR protocols and kits are now available or are being finalized. Other forms of test are also in use, such as immunofluorescence assays and serology, though their usage is low as compared to RIDTs and RT-PCRs.
"Key players"
The market is dominated by certain major players including Becton, Dickinson and Company, Roche Diagnostics, Alere, Quidel Corporation, and Thermo Fisher Scientific. The players are aim toward the development of cost-effective and technologically advanced diagnostic tests that are easier to use and facilitate fast antigen detection. The market is composed of players with strong brand value, such as Roche, BD, Alere and Thermo Fisher Scientific. Thus, it is expected that the market will be highly competitive in nature.
"Influenza diagnostics market outlook"
The influenza diagnostics market is anticipated to grow in the coming years, owing to factors such as increasing acceptance of in vitro diagnostic tests, a growing geriatric population base, and high prevalence of chronic disease conditions, such as respiratory, heart and blood disorders. The influenza diagnostics market is expected to record rapid growth due to RIDTs, which are gradually witnessing high adoption rates globally. Furthermore, the market is expected to grow further because of a large target population base in the APAC region with China and India leading the market.
In-depth report on global influenza diagnostics market by Grand View Research:
https://www.grandviewresearch.com/industry-analysis/influenza-diagnostics-market